ArticleMedicine2020

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.

Olivier Bylicki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.